Announcements Trials
Browse Landscape

Phase

Phase 2 11Phase 1 3Phase 1/2 1

Status

Completed 3

Sponsor Class

OTHER 2NIH 1

Study Type

Interventional 3

Sponsor

Cancer Type

Dermatologic 10Genitourinary 3Sarcoma 2CNS 1Breast 1

Conditions

Melanoma 2Carcinoma, Renal Cell 2Urinary Bladder Neoplasms 1Urethral Neoplasms 1

Interventions

pembrolizumab 93Nivolumab 61Docetaxel 55Cyclophosphamide 49enzalutamide 44Magnetic Resonance Spectroscopy 33Ipilimumab 33Gemcitabine 32Abiraterone Acetate 30Prednisone 29fludarabine 28Everolimus 27Paclitaxel 25Cisplatin 24Radiotherapy 23Carboplatin 23Sunitinib 22cabozantinib 21atezolizumab 20Radiosurgery 20Specimen Handling 19Sorafenib 18Bevacizumab 18pazopanib 17bicalutamide 17abiraterone 17Biopsy 15temsirolimus 14darolutamide 14apalutamide 14

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1 × Introns × Genitourinary × Clear all
NCT00629200 2018-11-15

Sodium Stibogluconate With Interferon Alpha-2b for Patients With Advanced Malignancies

M.D. Anderson Cancer Center

Phase 1 Completed
33 enrolled
DermatologicGenitourinary

Carcinoma, Renal Cell, Melanoma

NCT00082719 2015-05-14

Short-Term Low-Dose Interferon Alfa in Treating Patients With Cancer of the Urothelium

M.D. Anderson Cancer Center

Phase 1 Completed
33 enrolled
Genitourinary

Urinary Bladder Neoplasms, Urethral Neoplasms

NCT00217542 2013-05-03

Azacitidine and Recombinant Interferon Alfa-2b in Treating Patients With Stage III or Stage IV Melanoma or Stage IV Kidney Cancer That Cannot Be Removed By Surgery

National Cancer Institute (NCI)

Phase 1 Completed
42 enrolled
DermatologicGenitourinary

Carcinoma, Renal Cell, Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡